Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial

Preeta Tyagi; Chandra P. Belani

doi:10.1016/S1525-7304(11)70220-0

Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial

Preeta Tyagi
, Chandra P. Belani

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	276-278
Number of pages	3
Journal	Clinical Lung Cancer
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/S1525-7304(11)70220-0
State	Published - Mar 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/S1525-7304(11)70220-0

Cite this

@article{0c4f17e42af94d2f8e81caa312a93e22,

title = "Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial",

author = "Preeta Tyagi and Belani, \{Chandra P.\}",

year = "2005",

month = mar,

doi = "10.1016/S1525-7304(11)70220-0",

language = "English (US)",

volume = "6",

pages = "276--278",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer

T2 - Preliminary results from the ECOG 4599 trial

AU - Tyagi, Preeta

AU - Belani, Chandra P.

PY - 2005/3

Y1 - 2005/3

UR - https://www.scopus.com/pages/publications/20744440015

UR - https://www.scopus.com/pages/publications/20744440015#tab=citedBy

U2 - 10.1016/S1525-7304(11)70220-0

DO - 10.1016/S1525-7304(11)70220-0

M3 - Article

C2 - 15845177

AN - SCOPUS:20744440015

SN - 1525-7304

VL - 6

SP - 276

EP - 278

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -

Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this